Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Lukas Ochsner Ridder in
Google Scholar
PubMed
Department of Clinical Genetics and Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Agnethe Berglund in
Google Scholar
PubMed
Search for other papers by Kirstine Stochholm in
Google Scholar
PubMed
Unit for Thrombosis Research, Hospital of South West Jutland and University of Southern Denmark, Esbjerg, Denmark
Search for other papers by Simon Chang in
Google Scholar
PubMed
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
Unit for Thrombosis Research, Hospital of South West Jutland and University of Southern Denmark, Esbjerg, Denmark
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
(follicle-stimulating hormone, luteinizing hormone) and 65–85% of KS patients having decreased testosterone levels ( 6 ). KS patients may have signs of hypogonadism regardless of testosterone levels within the normal range. Even though current guidelines
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Search for other papers by Hanne Mumm in
Google Scholar
PubMed
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Marianne Andersen in
Google Scholar
PubMed
free testosterone ( 14 ). OCP may increase body weight ( 15 ) and insulin resistance ( 14 , 16 ), which could be associated with decreased GLP-1 levels. In contrast, animal studies suggested that estradiol and progesterone treatment could increase the
Search for other papers by Sebastian Franik in
Google Scholar
PubMed
Search for other papers by Kathrin Fleischer in
Google Scholar
PubMed
Search for other papers by Barbara Kortmann in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Kathleen D’Hauwers in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Jolanta Slowikowska-Hilczer in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Tim van de Grift in
Google Scholar
PubMed
Search for other papers by Audrey Cartault in
Google Scholar
PubMed
Search for other papers by Annette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Ute Thyen in
Google Scholar
PubMed
Search for other papers by Joanna IntHout in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by the dsd-LIFE group in
Google Scholar
PubMed
, psychological well-being, psychosexual outcome, testosterone treatment, fertility, experiences with care, and sexuality. To ensure confidentiality, the participants were asked to fill out the PRO with a secure password, either in the clinic or at home. Data were
Search for other papers by Jan Roar Mellembakken in
Google Scholar
PubMed
Search for other papers by Azita Mahmoudan in
Google Scholar
PubMed
Search for other papers by Lars Mørkrid in
Google Scholar
PubMed
Search for other papers by Inger Sundström-Poromaa in
Google Scholar
PubMed
Search for other papers by Laure Morin-Papunen in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, Helsinki, Uusimaa, Finland
Search for other papers by Juha S Tapanainen in
Google Scholar
PubMed
Search for other papers by Terhi T Piltonen in
Google Scholar
PubMed
Search for other papers by Angelica Lindén Hirschberg in
Google Scholar
PubMed
Search for other papers by Elisabet Stener-Victorin in
Google Scholar
PubMed
Department of Gynecology and Obstetrics, St. Olav’s Hospital, Trondheim, Norway
Search for other papers by Eszter Vanky in
Google Scholar
PubMed
Search for other papers by Pernille Ravn in
Google Scholar
PubMed
Search for other papers by Richard Christian Jensen in
Google Scholar
PubMed
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
PCOS is undetermined. Testosterone levels could be an important modifier of vascular health in PCOS, but whether testosterone has a protective or unfavorable impact on the risk of CVD in PCOS is debated ( 7 , 15 ). We are not aware of studies
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
puberty ↑AMH Small testes (onset mid-adolescence) Adolescent usually normal testosterone, but ↑ FSH, LH Speech and behavioral problems Adult primary hypogonadism 47,XYY Tall stature FSH ↑ but not to levels in XXY normal or
Search for other papers by Jan-Bernd Stukenborg in
Google Scholar
PubMed
Division of Haematology-Oncology and Stem Cell Transplantation, Children’s Hospital, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
Search for other papers by Kirsi Jahnukainen in
Google Scholar
PubMed
Search for other papers by Marsida Hutka in
Google Scholar
PubMed
Edinburgh Royal Hospital for Sick Children, Edinburgh, UK
Search for other papers by Rod T Mitchell in
Google Scholar
PubMed
in many other non-human primates, including the rhesus monkey and marmoset ( 7 , 8 ). In humans and non-human primates after the rise in gonadotrophins and testosterone during early infancy, there follows a period of relative HPG quiescence during
Department of Internal Medicine, Department of Clinical Sciences Malmö, Social Medicine and Global Health, University of Gothenburg, PO Box 454, SE-405 30 Gothenburg, Sweden
Search for other papers by Bledar Daka in
Google Scholar
PubMed
Search for other papers by Thord Rosen in
Google Scholar
PubMed
Search for other papers by Per Anders Jansson in
Google Scholar
PubMed
Search for other papers by Lennart Råstam in
Google Scholar
PubMed
Department of Internal Medicine, Department of Clinical Sciences Malmö, Social Medicine and Global Health, University of Gothenburg, PO Box 454, SE-405 30 Gothenburg, Sweden
Search for other papers by Charlotte A Larsson in
Google Scholar
PubMed
Search for other papers by Ulf Lindblad in
Google Scholar
PubMed
Introduction Sex hormone-binding globulin (SHBG) is a circulating plasma globulin binding sex hormones, both oestradiol and testosterone and is produced primarily by the liver. In two recent studies, SHBG could predict type 2 diabetes (T2D) in
Search for other papers by Karim Gariani in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
Testosterone - Testicles - Primary hypogonadism (congenital abnormalities, acquired diseases) - Secondary hypogonadism (pituitary disease (LH) or hypothalamic disease (GnRH)) Prolactin - Pituitary gland - Micro or macroprolactinoma - Stalk effect
Search for other papers by Sarah Byberg in
Google Scholar
PubMed
Search for other papers by Jesper Futtrup in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
-density lipoprotein (LDL), triglycerides (TRG), fasting plasma glucose, HOMA-IR, fasting serum insulin, glycated hemoglobin (HbA1c), plasma testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), high-sensitivity C-reactive protein (hsCRP) and
Search for other papers by Martin Zweifel in
Google Scholar
PubMed
Search for other papers by Beat Thürlimann in
Google Scholar
PubMed
Search for other papers by Salome Riniker in
Google Scholar
PubMed
Search for other papers by Patrik Weder in
Google Scholar
PubMed
Search for other papers by Roger von Moos in
Google Scholar
PubMed
Search for other papers by Olivia Pagani in
Google Scholar
PubMed
Search for other papers by Martin Bigler in
Google Scholar
PubMed
Search for other papers by Karin M Rothgiesser in
Google Scholar
PubMed
Search for other papers by Christiane Pilop in
Google Scholar
PubMed
Search for other papers by Hanne Hawle in
Google Scholar
PubMed
Search for other papers by Peter Brauchli in
Google Scholar
PubMed
Search for other papers by Coya Tapia in
Google Scholar
PubMed
Search for other papers by Wolfgang Schoenfeld in
Google Scholar
PubMed
Search for other papers by Cristiana Sessa in
Google Scholar
PubMed
Search for other papers by for the Swiss Group for Clinical Cancer Research (SAKK) in
Google Scholar
PubMed
Introduction For the treatment of breast cancer (BC), testosterone was already used extensively between the 1930s and 1960s with anecdotal tumour responses (especially in bone metastases) seen in up to 20% of treated women ( 1 , 2 , 3 , 4